3-EPI vitamin D.sub.2 compounds and uses thereof

Details 3-EPI vitamin D.sub.2 compounds and uses thereof 3-EPI vitamin D.sub.2 compounds and uses thereof

1998-05-15

2000-01-25

Clardy, S. Mark

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

9,10-seco- cyclopentanohydrophenanthrene ring system doai

552653, A01N 4500, C07C40100

Patent

active

060179082

ABSTRACT:
Novel 3-epi vitamin D2 compounds having the orientation of the substituent attached to the carbon at position 3 of the A-ring of vitamin D2 inverted from a beta (.beta.) to an alpha (.alpha.) configuration are described. These compounds were first identified as metabolites of vitamin D2 produced via a tissue-specific metabolic pathway which catalyzes the 3-.beta.-hydroxy epimerization of vitamin D2 compounds. The 3-epi vitamin D2 compounds of the present invention can be used as substitutes for natural and synthetic vitamin D.

REFERENCES:
patent: 4021423 (1977-05-01), Baggiolini et al.
patent: 4038272 (1977-07-01), Partridge, Jr. et al.
patent: 4595776 (1986-06-01), Baggiolini et al.
patent: 4711881 (1987-12-01), Ikekawa
patent: 4804502 (1989-02-01), Baggiolini et al.
patent: 5104864 (1992-04-01), DeLuca et al.
patent: 5145846 (1992-09-01), Baggiolini et al.
patent: 5401733 (1995-03-01), McLane et al.
patent: 5428029 (1995-06-01), Doran et al.
patent: 5547947 (1996-08-01), Dore et al.
patent: 5789607 (1998-08-01), Okabe
Coburn et al., 1.alpha.-(OH) Vit. D2: A new look at an "old" compound, Nephrol., dial. transplant, 11 (Suppl. 3, Renal Bone Disease, Parathyroid Hormone and Vit. D), 153-7, 1996.
Mahe et al., Structure and Chemistry of pi.-allyl Pd complexes from Steroids, J. Chem. Soc., Perkin Trans. 1, (9), 2504-8, 1981.
Mosekilde et al., Low serum levels of 1,25 (OH).sub.2 vitamin D, Med. Dep. III, Aarhus County Hosp., Aarhus, Den. Gut, 21(7), 624-31, 1980.
Cota, J.G. et al. "Hydrotitanation-Protonationof Vitamin D.sub.2 and Its Analogues: An Efficient Method for Preparation of 10,19-Dihydrovitamins D.sub.2 Including Dihydrotachysterol.sub.2 " J. Org. Chem. 53(26):6094-6099 (1988);.
Maestro, Miguel a. et al. "A Convergent Approach to the Dihydrotachysterol Diene System. Application to the Synthesis of Dihydrotachysterol.sub.2 (DHT.sub.2), 25-Hydroxydihydrotachysterol .sub.2 (25-OH-DHT.sub.2), 1-(r), 19-Dihydro-(5E)-3-epivitamin D.sub.2, and 25-Hydroxy-10(r), 19-Dihydro-(5E)-3-epivitamin D.sub.2 " J. Org. Chem. 57:5208-5213 (1992);.
Muralidhara, K.R. et al. "Studies on the A-Ring Diastereomers of 1.alpha., 25-Dihydroxyvitamin D.sub.3.sup.la " J. Org. CHem. 58:1895-1899 (1993).
Holmberg et al., Scand J. Clin. Lab. Invest, 46(8), (1986) (abstract).
Jones et al., Biochemistry 18(6), 1094-101 (1979) (abstract).
Loibner et al., Tetrahedron, 34(6), 713-16 (1978) (abstract).
Berman et al., J. Org. Chem., 42(21), 3225-330 (1977) (abstract).
Stern et al., Mol. Pharmacol., 12(6), 879-86 (1976) (abstract).
Jones et al., Biochemistry 14(6), 1250-6 (1975) (abstract).
Baggiolini, E. et al., "Stereocontrolled Total Synthesis of 1-60 25-Dihydroxycholecalciferol and 1.alpha. ,25-Dihydroxyergocalciferol," J. Org. Chem., vol. 51, 3098-3108 (1986);.
Bishop, J. et al., "Profile of Ligand Specificity of the Vitamin D Binding Protein for 1-60 ,25-Dihydroxyvitamin D.sub.3 and its Analogs," Journal of Bone and Mineral Research, vol. 9, No. 8, 1277-88 (1994);.
Bouillon, R. et al., "Biologic Activity of Dihydroxlated 19-Nor-(Pre) Vitamin D.sub.3 ," Journal of Bone and Mineral Research, vol. 8, No. 8, 1009-15 (1993);.
Bouillon, R. et al., "Structure-Function Relationships in the Vitamin D Endocrine System," Endocrine Reviews, vol. 16, No. 2, 200-57. (1995);.
Campbell, M. et al., "Vitamin D.sub.3 Analogs and Their 24-Oxo Metabolites Equally Inhibit Clonal Proliferation of a Variety of Cancer Cells but Have Differing Molecular Effects," Journal of Cellular Biochemsitry, vol. 66 413-25 (1997).
Cross, H. et al., "Vitamin D Metabolism in Human Colon Adenocarcinoma-derived Caco-2 Cells: Expressionof 25-Hydroxyvitamin D.sub.3 -1.alpha.-hydroxylase Activity and Regulation of Side-chain Metabolism," J. Steorid Biochem., Molec. Biol., vol. 62, No. 1, 21-8 (1997);.
de Vos, S. et al., "Effects of Potent Vitamin D.sub.3 Analogs on Clonal Proliferation of Human Prostate Cancer Cell Lines," The Prostate, vol. 31, No. 2, 77-83 (1997).
Dusso, A.S. et al., "On the Mechanisms for the Selective Actionof Vitamin D Analogs," Endocrinology, vol. 128, No. 4, 1687-92 (1991);.
Fioravanti, L. et al., "Synthetic Analogs of Vitamin D.sub.3 Have Inhibitory Effects on Breast Cancer Cell Lines," Anticancer Research, vol. 18, 1703-8 (1998);.
Fleet, J. et al., "1.alpha.,25-(OH).sub.2 -Vitamin D.sub.3 Analogs with Mineral in Vivo Calcemic Activity Can Stimulate Significant Transepithelial Calcium Transport and mRNA Expression in Vitro," Archives of Biochemistry and Biophysics, vol. 329, No. 2, 228-34 (1996);.
Fleet, J.C. et al., "Effect of A-Ring Diastereomers of 1.alpha.,25-Dihydroxy Vitamin D.sub.3 on Calcium Transport in Caco-2 Cells," FASEB J., vol. 9, No. 3, 168 (1995);.
Gardner, J. et al., "Vitamin D Analog 25-(OH)-16,23E-Diene-26,27-Hexafluoro-Vitamin D.sub.3 Induces Differentiation of HL60 Cells with Miminial Effects on Cellular Calcuim Homeostasis," Journal of Cellular Biochemsitry, vol. 63, 500-12 (1996);.
Jung, S. et al., "1,25(OH).sub.2 -16ENE-Vitamin D.sub.3 is a Potent Antileukemic Agent with Low Potential to Cause Hypercalcemia," Leukemia Research, vol. 18, No. 6, 453-63 (1994);.
Kim, H. et al., "1,25-Dihydroxy-Vitamin-D.sub.3 Enhances Antiproliferative Effect and Transcription of TGF-.beta.1 on Human Keratinocytes in Culture," Journal of Cellular Physiology, vol. 151, 579-87 (1992);.
Koszewski, N. et al., "24,26-Dihydroxyvitamin D.sub.2 : A Unique Physiological Meatbolite of Vitamin D.sub.2'," Biochemsitry, vol. 27, 5785-90 (1988);.
Lemire, J. et al., "1,25-Dihydroxy-24-OXO-16ene-Vitamin D3, a Renal Metabolite of the Vitamin D Analog 1,25-Dihydroxy-16ene-vitamin D3, Exerts Immunosuppressive Activity Equal to its Parent Without Causing Hypercalcermia in vivo," Endocrinology, vol. 135, No. 6, 2818-21 (1994);.
Mayer, E. et al., "23,25-Dihydroxy-24-oxovitamin D.sub.3 : A Metabolite of Vitamin D.sub.3 Made in the Kidney," Biochemistry, vol. 22, No. 8, 1798-1805 (1983);.
Norman, E. et al., "Demonstration That 1.beta.,25-Dihydroxyvitamin D.sub.3 is an Antagonist of the Nongenomic but not Genomic Biological Responses and Biological Profile of the Three A-ring Diastereomers of 1.alpha.,25-Dihydroxyvitamin D.sub.3," The Journal of Biological Chemistry, vol. 268, No. 27, 20022-30 (1993);.
Reddy, G.S., "Isolation and Identification of 1,24,25-Trihydroxyvitamin D.sub.2, 1,24,25,28-Tetrahydroxyvitamin D.sub.2 and 1,24,25,26-Tetrahydroxyvitamin D.sub.2 : New Metabolites of 1,25-Dihydroxyvitamin D.sub.2 Produced in Rat Kidney," Biochemistry, vol. 25, 5328-36 (1986);.
Reddy, G.S. and Tserng, K-Y, "24,25,28-Trihydroxyvitamin D.sub.2 and 24,25,26-Trihydroxyvitamin D.sub.2 : Novel Metabolites of Vitamin D.sub.2," Biochemistry, vol. 29, 943-9 (1990);.
Reddy, G.S. and Tserng, KY, "Calcitroic Acid, End Product of Renal Metabolism of 1,25-Dihydroxyvitamin D.sub.3 Through C-24 Oxidation Pathway," Biochemistry, vol. 28, 1763-9 (1989);.
Reddy, G.S. et al., "Metabolism of 1a,25-Dihydroxyvitamin D.sub.3 and One of its A-Ring DIastereomer 1a,25-Dihydroxy-3-Epivitamin D.sub.3 in Neonatal Human Keratinocytes," Vitamin D: A Pluripotent Steroid Hormone: Structural Studies, Molecular Endocrinology and Clinical Applications, Prodeedings of the Ninth Workshop on Vitamin D, Orlando, FL, 172-3 (May 26-Jun. 2, 1994).
Reddy, G.S. et al., "Stimulation of 24R,25-dihydroxyvitamin D.sub.3 Synthesis by Metabolites of Vitamin D.sub.3," Am. J. Physiol., vol. 245, No. 4 E359-64 (1983);.
Reddy, G.S. et al., "Study of 1,25-Dihydroxyvitamin D.sub.3 Induced Alterations in the Metabolism of [.sup.3 H]25-Hydroxyvitamin D.sub.3 Using Isolated Perfused Kidneys From D-Sufficient Rats," Biochemical and Biophysical Research Communications, vol. 107, No. 3, 922-8 (1982);.
Reichel, H. and Norman, A., "Systemic Effects of Vitamin D," Ann. Rev. Med., vol. 40, 71-8 (1989);.
Schwartz, G. et al., "1,25-Dihydroxy-16-ENE-23-YNE-Vitamin D.sub.3 and Prostate Cancer Cell Proliferation in Vivo," Urology, vol. 46, No. 3, 365-9 (1995);.
Siu-Caldera, ML et al., "The Enhanced Biological Activties Ascribed to its Parent Analog, 1.alpha. ,25(OH).sub.2 -16-ene-D.sub.3," J. Steroid Biochem. Molec. Bi

Affiliated with

Also associated with

Rating

3-EPI vitamin D.sub.2 compounds and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 3-EPI vitamin D.sub.2 compounds and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-EPI vitamin D.sub.2 compounds and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2316053